Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B, Randomized, Controlled Study of HTX-011 Administered Via Pectoral Nerve Block in Subjects Undergoing Upper Extremity Surgery for Augmentation Mammoplasty

Next Previous
X
Search
Trial Profile

A Phase 2B, Randomized, Controlled Study of HTX-011 Administered Via Pectoral Nerve Block in Subjects Undergoing Upper Extremity Surgery for Augmentation Mammoplasty

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine/meloxicam (Primary) ; Bupivacaine
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Heron Therapeutics

    • Most Recent Events

    • 05 Oct 2020 Results of pooled analysis of data pooled from 4 studies assessing the safety and plasma concentrations of various doses of HTX-011 in a variety of surgical sites with differing vascularity, presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists
    • 21 Jun 2018 Primary endpoint (Mean area under the curve (AUC) of the NRS-R pain intensity scores) has been met, according to the Heron Therapeutics media release.
    • 21 Jun 2018 Results presented in the Heron Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top